Your browser doesn't support javascript.
loading
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
Rule, S; Jurczak, W; Jerkeman, M; Rusconi, C; Trneny, M; Offner, F; Caballero, D; Joao, C; Witzens-Harig, M; Hess, G; Bence-Bruckler, I; Cho, S-G; Thieblemont, C; Zhou, W; Henninger, T; Goldberg, J; Vermeulen, J; Dreyling, M.
Afiliación
  • Rule S; Plymouth University Medical School, Plymouth, UK. Simon.Rule@nhs.net.
  • Jurczak W; Department of Hematology, Jagiellonian University, Krakow, Poland.
  • Jerkeman M; Skånes University Hospital, Lund University, Lund, Sweden.
  • Rusconi C; Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
  • Trneny M; Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic.
  • Offner F; Departement Oncologie, UZ Gent, Ghent, Belgium.
  • Caballero D; Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
  • Joao C; Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal.
  • Witzens-Harig M; Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany.
  • Hess G; Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany.
  • Bence-Bruckler I; The Ottawa Hospital, General Campus, Ottawa, ON, Canada.
  • Cho SG; Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea.
  • Thieblemont C; APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France.
  • Zhou W; Janssen Research & Development, Raritan, NJ, USA.
  • Henninger T; Janssen Research & Development, Raritan, NJ, USA.
  • Goldberg J; Janssen Research & Development, Raritan, NJ, USA.
  • Vermeulen J; Janssen Research & Development, Leiden, The Netherlands.
  • Dreyling M; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.
Leukemia ; 32(8): 1799-1803, 2018 08.
Article en En | MEDLINE | ID: mdl-29572505
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Linfoma de Células del Manto Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Linfoma de Células del Manto Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido